Photo of Tariq Kewan taken from Yale Cancer Center/LinkedIn
Dec 16, 2023, 16:26
TP53 has a negative impact on survival, but not on response to HMA – Yale Cancer Center
Quoting Yale Cancer Center on X/Twitter:
“Tariq Kewan, presents a review of VALIDATE database of MDS pts with TP53 treated with HMA ASH23:
– TP53 has a negative impact on survival, but not on response to HMA,
– Patients with TP53 have poor outcomes and need of new therapies.”
Source: Yale Cancer Center/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12
Dec 21, 2024, 11:06
Dec 21, 2024, 10:38